• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mydecine Innovations Group Inc (OP: MYCOF )

    0.0040 -0.0013 (-24.53%)
    Streaming Delayed Price Updated: 2:54 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,278
    Open 0.0041
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0053
    Today's Range 0.0028 - 0.0041
    52wk Range 0.0001 - 0.0300
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
    Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support. 
    Via Benzinga
    EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
    Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
    Via Benzinga

    Performance

    YTD
    -65.22%
    -65.22%
    1 Month
    -27.27%
    -27.27%
    3 Month
    -41.18%
    -41.18%
    6 Month
    -60.00%
    -60.00%
    1 Year
    -75.61%
    -75.61%

    More News

    Read More
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Board Approves Issuance of Shares for Debt Settlement
    Via Investor Brand Network
    Mydecine Innovations Group Inc. Announces Share for Debt Settlement
    Via TheNewswire.com
    Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
    Via Benzinga
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Compounds Receive USPTO Notice of Allowances
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property Product Safety
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces USPTO Issues Notice of Allowance for MYCO-005 Compound
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property Product Safety
    Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
    From Mydecine Innovations Group Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Updates Special Access Program
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Files Prospectus Supplement, Closes Share Subscription Agreements
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Reports on Company Progress in Q4 2023 Update
    Via Investor Brand Network
    Exposures Product Safety
    Mydecine Provides Q4 2023 Business Update
    From Mydecine Innovations Group Inc.
    Via GlobeNewswire
    Mydecine Innovations Group gearing up for human trials after completing Aquis listing
    Via News Direct
    Mydecine Innovations Group gearing up for human trials after completing Aquis listing
    Via TheNewswire.com
    Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
    Via Benzinga
    Exposures Product Safety
    Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market
    Via Benzinga
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Starts Trading on the AQSE Growth Market
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property Product Safety
    Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
    From Mydecine Innovations Group Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) Common Shares Begin Listing on CSE
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Expects UK Dual Listing Admission Next Month
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Receives CSE Listing Conditional Approval
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    Mydecine Announces Conditional Approval of CSE Listing
    From Mydecine Innovations Group Inc.
    Via GlobeNewswire
    Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
    Via Benzinga
    Topics Cannabis Economy
    Exposures Cannabis Interest Rates
    Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
    Via Benzinga
    Jamaica Launches Organic Psilocybin Gummies & New Psychedelic Retreat: Rose Hill's New Offer
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.